Hubei Jumpcan Pharmaceutical (600566) H1 2025 earnings summary

Executive summary

• Revenue for H1 2025 was RMB 2.75 billion, down 31.87% year-over-year, with net profit attributable to shareholders at RMB 724 million, down 45.87%.

• Declines were mainly due to reduced demand for core products and the impact of centralized procurement policies.

• R&D advanced with new drug approvals and clinical trial progress; digital transformation and talent development continued.

Financial highlights

• Operating income: RMB 2.75 billion, down 31.87% year-over-year.

• Net profit attributable to shareholders: RMB 724 million, down 45.87% year-over-year.

• Operating cash flow: RMB 972 million, down 37.95% year-over-year.

• Basic and diluted EPS: RMB 0.78, down 46.21% year-over-year.

• Gross margin and net margin both declined due to lower sales and policy pressures.

Outlook and guidance

• The company will focus on product pipeline diversification, digital transformation, and expanding retail and e-commerce channels to mitigate policy and market risks.

• Continued investment in R&D and innovation to strengthen long-term competitiveness.